Key result
This paper provides a detailed protocol for evaluating the contractility of diaphragmatic muscle fibers in SEPN1 knockout mice following chronic treatment with tauroursodeoxycholic acid.
Why the study?
Loss-of-function mutations in the gene encoding for SEPN1 give rise to myopathy, prompting a protocol to evaluate diaphragmatic muscle fiber contractility following chronic TUDCA treatment.
This paper provides a detailed protocol for evaluating the contractility of diaphragmatic muscle fibers in SEPN1 knockout mice following chronic TUDCA treatment.
Provides standardized protocol for diaphragm assessment in SEPN1 models; hypothesis-generating and leaves open clinical translation.
Selenoprotein N1 (SEPN1) is a type II endoplasmic reticulum (ER) glycoprotein. Loss-of-function mutations in the gene encoding for SEPN1 give rise to myopathy. Here, we present a protocol for evaluating the contractility of diaphragmatic muscle fibers of SEPN1 knockout mice following chronic treatment with tauroursodeoxycholic acid (TUDCA). We describe steps for genotyping SEPN1 knockout mice, TUDCA in vivo treatment, diaphragm dissection, and chemical permeabilization. We then detail procedures for single muscle fiber isolation and tension measurement. For complete details on the use and execution of this protocol, please refer to Germani et al. 1
No takes yet. Share an insight, caveat, or question.
Nogara et al. (2025) studied SEPN1-related myopathy. Tauroursodeoxycholic acid (TUDCA) vs. Water (placebo) was evaluated on Normalized tension produced by a skinned fiber under saturating calcium concentration. This paper provides a detailed protocol for evaluating the contractility of diaphragmatic muscle fibers in SEPN1 knockout mice following chronic treatment with tauroursodeoxycholic acid.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: